Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2019 / Articles / Jan / When Noses Counterattack
Discovery & Development Drug Discovery Drug Delivery Translational Science Research News Drug Delivery Development & Clinical Sponsored

When Noses Counterattack

Mimicking the exomes secreted by nasal cells in response to bacteria could boost drug uptake

By Maryam Mahdi 01/22/2019 0 min read

Share

Each breath we take gives bacteria the opportunity to infiltrate our airways. Fortunately, our noses have their own effective mechanisms of defense. Researchers at Massachusetts Eye and Ear claim to have observed, for the first time, cells in the front of the nose detecting pathogenic bacteria in the nasal cavity. In response to bacteria, the cells release swarms of exosomes into the nasal mucus to attack invading microbes. “This is one of the only examples where the immune system actually extends outside the body (in this case into the airway) to fight off bacteria,” says Benjamin Bleier, Associate Professor of Otolaryngology at Massachusetts Eye and Ear and senior author of a new study (1). “The detection of lipopolysaccharide molecular signatures in pathogenic bacteria triggers increased numbers of exosomes, packaged with antimicrobial molecules, to be released.”

The exosomes employ a two-prong approach to defense: attacking bacteria directly with potency equivalent to antibiotics, and donating their antimicrobial proteins to epithelial cells by moving to the back of the nose through the natural mucus blanket where they are absorbed.

“The idea for this research came from our previous studies looking into the causes of chronic rhinosinusitis. We discovered that exosomes were secreted into the nasal mucus and were able to transport pro-inflammatory proteins between cells. However, in our healthy control patients, we also saw billions of exosomes being secreted, which led us to question what their role was in the normal healthy nose,” explains Bleier. Though research at the time had explored the role of exosomes in gut cell cultures, no such information existed in regard to the nose.

Exosomes transport proteins between nasal epithelial cells on time scales that outpace mucociliary clearance (the movement of cilia on mucosal respiratory surfaces). According to Bleier, the efficiency of drug uptake via the nose could be improved if therapeutics were designed to mimic exosomes. However, as the composition of exosomes is similar to their host cells, they would likely trigger an immune response when introduced to a new host. Therefore, novel exosome-based therapeutics would need to allow rapid cellular uptake to occur, without eliciting an immune response.

“As exosomes are ubiquitous within the body, it is highly likely that they have a similar role in other organ systems too,” adds Bleier. “Recent studies have also highlighted the cross-talk between the immune system and the human microbiome, so exosomes may also be responsible for maintaining a healthy commensal community in the nose by targeting pathogenic bacteria and tolerating healthy microbes.”

Bleier and his team now plan to conduct large-scale bioinformatic studies to correlate the exosome proteome to the nasal microbiome, which could also have implications in understanding and treating chronic infectious and inflammatory disorders of the nose and sinuses.

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. AL Nocera et al., “Exosome swarms eliminate airway pathogens and provide passive epithelial immunoprotection through nitric oxide”, Journal of Allergy and Clinical Immunology, 18 (2018).

About the Author(s)

Maryam Mahdi

After finishing my degree, I envisioned a career in science communications. However, life took an unexpected turn and I ended up teaching abroad. Though the experience was amazing and I learned a great deal from it, I jumped at the opportunity to work for Texere. I'm excited to see where this new journey takes me!

More Articles by Maryam Mahdi

False

Advertisement

Recommended

False

Related Content

Understanding the H5N1 Threat
Vaccines Drug Discovery
Understanding the H5N1 Threat

February 3, 2025

4 min read

With new cases of avian influenza appearing, what does this mean for global health and what are drug developers doing about it?

Battle of the Superbugs
Drug Discovery Technology and Equipment
Battle of the Superbugs

December 1, 2014

0 min read

Can phage endolysins revolutionize the way bacterial infections are treated – and prevent drug resistance?

Antibiotics: Going With the Flow
Drug Discovery Small Molecules
Antibiotics: Going With the Flow

April 2, 2025

2 min read

How fluid flow through the body can affect the ways in which antibiotics work.

Combatting the Side Effects of Treatments for Parkinson’s
Drug Discovery Small Molecules
Combatting the Side Effects of Treatments for Parkinson’s

April 7, 2025

4 min read

Celon Pharma CEO hopes their new compound could be a potential breakthrough for Parkinson’s patients.

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.